– Epidiolex U.S. Q1 net sales of $33.5m — Positive Phase 3 pivotal results in Tuberous Sclerosis Complex, sNDA submission expected in Q4 2019 — Conference call today at 4:30 p.m. EDT –
CARLSBAD, Calif., May 06, 2019 (GLOBE NEWSWIRE) – GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development and commercialization of cannabinoid prescription medicines, announces financial results for the first quarter ended March 31, 2019.
“We are pleased to report a strong launch of Epidiolex in the US and continue to be encouraged by the level of support for this medicine from patients, caregivers and healthcare professionals. As the first and only plant-derived CBD medicine approved by the FDA, Epidiolex offers a novel treatment option for patients with Lennox-Gastaut Syndrome and Dravet syndrome, two highly treatment-resistant forms of childhood-onset epilepsy”, stated Justin Gover, GW’s Chief Executive Officer. “In addition, we are delighted to report today positive results from a Phase 3 trial in patients with seizures associated with Tuberous Sclerosis Complex, and are excited at the prospect of expanding the use of Epidiolex to these high need patients in the future.”
OPERATIONAL HIGHLIGHTS
Darren Cline appointed U.S. Chief Commercial Officer
Epidiolex®(cannabidiol)
U.S. commercial update
Q1 Net sales of $33.5m
Over 7,600 patients have received Epidiolex prescriptions since launch
Over 1,900 physicians have generated dispensed prescriptions since launch
Pharmacy distribution network now includes over 145 distribution points
Approximately 75 percent of 900 patients in expanded access program and open label extension now transitioned to commercial product. Remaining patients expected to transition by end of Q2.
Rapid and encouraging payor coverage decisions
Over 90 percent of all U.S. lives now covered – 65 percent of which have either Prior Authorization (PA) to indication or less restrictive
New commercial coverage determination recently announced by United HealthCare, OptumRx and Prime Therapeutics
99 percent of State Fee-for-Service Medicaid lives now have a coverage determination with 67 percent of covered lives having either PA to indication or less restrictive
7 States covering Epidiolex without restrictions
Approximately 90 percent of Managed Medicaid lives have a coverage determination with 40 percent having a PA to indication or less restrictive
Target physician coverage
The sales organization has to date interacted with about 70 percent of the over 5,000 target healthcare professionals including all Level 3 and 4 epilepsy centers
European regulatory and pre-launch progress
CHMP opinion expected mid-2019
Launches expected in major five European markets by end of 2019
Manufacturing
Commercial manufacturing and supply chain running smoothly
Production capacity sufficient to meet expected demand in both U.S. and Europe
Clinical trials
Positive results in Phase 3 trial in Tuberous Sclerosis Complex
Primary efficacy measure achieved with both Epidiolex doses compared to placebo
sNDA submission expected in Q4 2019
IND open for pivotal Phase 3 trial in Rett Syndrome with expected start in Q2 2019
Life-cycle management
Several new formulations of CBD in development including modified oral solution, capsule and intravenous formulation
Exclusivity
7 years of orphan exclusivity confirmed by FDA, plus 6-month pediatric extension expected. 10 years of orphan exclusivity in Europe plus 2 year pediatric extension
Key favorable patent grants by USPTO related to the use of CBD in epilepsy
Patents align directly with new Epidiolex FDA label and listed in “Orange Book”
Patent expiry dates to 2035
Additional patent applications under review, including patents related to the use of Epidiolex in TSC
Pipeline progress
Sativex®(nabiximols)
FDA meeting in December 2018 resulted in regulatory pathway in the U.S.
Initial U.S. target indication: Multiple Sclerosis spasticity
Single Phase 3 pivotal study expect to commence in Q4 2019
Over 10 placebo-controlled trials already completed in other indications, representing significant U.S. lifecycle management opportunities
CBDV
Initial data from 5 patient expanded access program in patients with seizures and autism presented at American Epilepsy Society Annual Meeting suggest that CBDV is well tolerated and has potential as an AED/behavioral/cognitive medicine in the autism/epilepsy population
Company sponsored IND open for 30-patient open label study in autism
Investigator-led 100 patient placebo-controlled trial in autism spectrum disorder has commenced recruitment
Open label study in Rett syndrome and seizures has commenced
FINANCIAL HIGHLIGHTS
Cash and cash equivalents at March 31, 2019 were $521.7 million compared to $591.5 million as of December 31, 2018
Revenue for the quarter ended March 31, 2019 was $39.2 million compared to $3.0 million for the quarter ended March 31, 2018
Net loss for the quarter ended March 31, 2019 was $50.1 million compared to $69.5 million for the quarter ended March 31, 2018
Closed transaction to sell Rare Pediatric Disease Priority Review Voucher for $105 million on April 5, 2019. The sale will be reflected in our Q2 2019 results
Conference Call and Webcast InformationGW Pharmaceuticals will host a conference call and webcast to discuss the quarter ending March 31, 2019 financial results today at 4:30 pm EDT. To participate in the conference call, please dial 877-407-8133 (toll free from the U.S. and Canada) or 201-689-8040 (international). Investors may also access a live audio webcast of the call via the investor relations section of the Company’s website athttp://www.gwpharm.com. A replay of the call will also be available through the GW website shortly after the call and will remain available for 90 days. Replay Numbers: (toll free):1-877-481-4010 or 919-882-2331 (international). For both dial-in numbers please use conference Replay ID: 47716.
About GW Pharmaceuticals plc and Greenwich Biosciences, Inc.Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW, along with its U.S. subsidiary Greenwich Biosciences, has received U.S. FDA approval for EPIDIOLEX (cannabidiol) oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older and which is now available by prescription in the U.S. The Company has submitted a regulatory application in Europe for the adjunctive treatment of seizures associated with LGS and Dravet syndrome. The company continues to evaluate EPIDIOLEX in additional rare epilepsy conditions including Tuberous Sclerosis Complex (TSC) andRett syndrome. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States and for which the company is now planning a U.S. Phase 3 trial. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for epilepsy, glioblastoma, and schizophrenia. For further information, please visitwww.gwpharm.com.
Forward-looking statementsThis news release contains forward-looking statements that reflect GW’s current expectations regarding future events, including statements regarding financial performance, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the relevance of GW products commercially available and in development, the clinical benefits of EPIDIOLEX (cannabidiol) oral solution and Sativex (nabiximols) and the safety profile and commercial potential of EPIDIOLEX and Sativex. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of GW’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, and the acceptance of Sativex, EPIDIOLEX and other products by consumer and medical professionals. A further list and description of risks and uncertainties associated with an investment in GW can be found in GW’s filings with the U.S. Securities and Exchange Commission, including the most recent Form 10-KT filed on 26 February 2019. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
Enquiries:
GW Pharmaceuticals plc
Stephen Schultz, VP Investor Relations (U.S.)
917 280 2424 / 401 500 6570
U.S. Media Enquiries:Sam Brown Inc. Healthcare Communications
Christy CurranMike Beyer
615 414 8668312 961 2502
EU Media Enquiries:FTI Consulting
Ben Atwell/Andrew Ward
+44 (0) 20 727 1000
GW PHARMACEUTICALS PLCCONDENSED CONSOLIDATED BALANCE SHEETS(in thousands, except share data)(unaudited)
March 31,
December 31,
2019
2018
Assets
Cash and cash equivalents
$
521,669
$
591,497
Accounts receivable, net
19,251
4,192
Inventory
48,559
33,030
Prepaid expenses and other current assets
19,389
17,903
Total current assets
608,868
646,622
Property, plant, and equipment, net
102,029
90,832
Operating lease assets
20,077
–
Goodwill
6,959
6,959
Deferred tax assets
8,584
8,720
Other assets
3,040
2,935
Total assets
$
749,557
$
756,068
Liabilities and stockholders’ equity
Accounts payable
$
10,794
$
9,796
Accrued liabilities
59,782
52,477
Current tax liabilities
1,730
2,384
Other current liabilities
5,651
1,559
Total current liabilities
77,957
66,216
Long-term liabilities:
Finance lease liabilities
5,801
5,690
Operating lease liabilities
16,374
–
Other liabilities
9,696
10,082
Total long-term liabilities
31,871
15,772
Total liabilities
109,828
81,988
Commitments and contingencies
Stockholders’ equity:
Ordinary shares par value £0.001; 368,613,440 shares
outstanding as of March 31, 2019; 366,616,688 sharesoutstanding as of December 31, 2018
567
564
Additional paid-in capital
1,593,056
1,581,144
Accumulated deficit
(879,004
)
(828,940
)
Accumulated other comprehensive loss
(74,890
)
(78,688
)
Total stockholders’ equity
639,729
674,080
Total liabilities and stockholders’ equity
$
749,557
$
756,068
GW PHARMACEUTICALS PLCCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except share and per share amounts)(unaudited)
Three Months Ended March 31,
2019
2018
Revenues
Product net sales
$
38,974
$
2,812
Other revenue
273
229
Total revenues
39,247
3,041
Operating expenses
Cost of product sales
5,131
1,625
Research and development
30,375
43,485
Selling, general and administrative
55,078
26,173
Total operating expenses
90,584
71,283
Loss from operations
(51,337
)
(68,242
)
Interest income
2,087
759
Interest expense
(265
)
(325
)
Foreign exchange loss
(1,114
)
(640
)
Loss before income taxes
(50,629
)
(68,448
)
Income tax (benefit) expense
(565
)
1,013
Net loss
$
(50,064
)
$
(69,461
)
Net loss per common share, basic and diluted
$
(0.14
)
$
(0.20
)
Weighted average common shares outstanding, basic and diluted
369,823
340,252
GW PHARMACEUTICALS PLCCONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands)(unaudited)
Three Months Ended March 31,
2019
2018
Cash flows from operating activities
Net loss
$
(50,064
)
$
(69,461
)
Adjustments to reconcile net loss to net cash used in operating activities:
Foreign exchange loss
797
873
Stock-based compensation
11,142
6,859
Depreciation and amortization
2,417
2,307
Deferred income taxes
–
2,128
Changes in operating assets and liabilities:
Accounts receivable, net
(14,998
)
(320
)
Inventory
(14,295
)
672
Prepaid expenses and other current assets
(874
)
(492
)
Other assets
659
(3
)
Accounts payable
1,998
652
Current tax liabilities
(654
)
(2,684
)
Accrued liabilities
6,328
(7,005
)
Other current liabilities
191
1,103
Long-term liabilities
(1,029
)
(30
)
Net cash used in operating activities
(58,382
)
(65,401
)
Cash flows from investing activities
Additions to property, plant and equipment
(12,087
)
(6,056
)
Additions to capitalized software
(199
)
(338
)
Net cash used in investing activities
(12,286
)
(6,394
)
Cash flows from financing activities
Proceeds from exercise of stock options
773
1
Payments on finance leases
(179
)
(72
)
Payments on landlord financing obligation
(138
)
(137
)
Net cash provided by (used in) financing activities
456
(208
)
Effect of exchange rate changes on cash
384
11
Net increase (decrease) in cash and cash equivalents
(69,828
)
(71,992
)
Cash and cash equivalents at beginning of period
591,497
559,227
Cash and cash equivalents at end of period
$
521,669
$
487,235
Get Real-Time Updates from The Daily Marijuana Observer
